Anti-Influenza Pharm

Question 1

MOA of neuraminidase inhibitors

Answer 1

inhibit neuraminidase –> bunching of newly released influenza virions to each other and clumping of virions to the membrane of the infected host cell

Question 2

spectrum of activity for neuraminidase inhibitors

Answer 2

influenza A and B viral strains

Question 3

resistance to neuraminidase inhibitors

Answer 3

can develop but is rare

Question 4

when should initiation of neuraminidase inhibitors occur

Answer 4

48 hours after onset

Question 5

adverse effects neuraminidase inhibitors

Answer 5

increased risk of hallucinations, delirium, and abnormal behavior

Question 6

adverse effects of Oseltamivir

Answer 6

• nausea, vomiting, HA

- fatigue and diarrhea more common with prophylactic use

Question 7

adverse effects Zanamivir

Answer 7

• cough, bronchospasm, reversible decrease in pulm function, transient nasal and throat discomfort

Question 8

compare how the three neuraminidase inhibitors are administered

Answer 8

oseltamivir: oral
zanamivir: inhalation
permivir: single IV dose

Question 9

adverse effects Peramivir

Answer 9

• diarrhea (more common)

- skin or hypersensitivity reactions

Question 10

MOA of adamantanes

Answer 10

block M2 proton ion channel of virus particle and inhibit coating of viral RNA within infected cells, preventing replication

Question 11

spectrum of activity for adamantanes

Answer 11

influenza A viral strands

Question 12

resistance to adamantanes

Answer 12

high rates in H1N1 and H3N2

not commonly used in tx or prevention of influenza

Question 13

how are adamantanes administered

Answer 13

orally

Question 14

adverse effects adamantanes

Answer 14

• nausea, anoerxia, nervousness, difficulty in concentrating, insomnia, light-headedness
• birth defects

Question 15

list the two adamantanes mentioned

Answer 15

amantadine

rimantadine